# OnCo record natco (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/natco/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "natco" ;
  schema:name "Natco Pharma"@en ;
  schema:description "The oncology generics company at the centre of India's two landmark patent fights: the first compulsory licence, for sorafenib in 2012, and the Supreme Court's 2013 refusal of Novartis's imatinib patent."@en ;
  schema:url <https://onco.cc/companies/natco/>, <https://www.natcopharma.co.in> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Natco_Pharma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1966372> ;
  schema:citation <https://www.natcopharma.co.in>, <https://en.wikipedia.org/wiki/Novartis_v._Union_of_India_%26_Others> ;
  schema:addressCountry "IN" ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/pomalidomide/> ;
  onco:trials <https://onco.cc/trials/nct05283226/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-ip-collaboration/> .